Crandi

Patient Information Contact Sohonos Com

Leo Migdal
-
patient information contact sohonos com

SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and children (aged 8 years and above for females and 10... SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. Patient Education Liaisons (PELs) are healthcare educators who can provide educational information to you, your family members, and caregivers related to FOP and SOHONOS. Your regional PEL can work with you in connection with your doctor to support you and your family. I understand that a PEL from Ipsen will not provide any medical advice and is not my doctor or part of my doctor’s office. By submitting this form, I agree to Ipsen’s Privacy Policy.

I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Privacy Policy. I understand that Ipsen will use reasonable measures to protect the information I share with the PEL and will not use or disclose it outside of Ipsen. The IPSEN CARES® Patient Support Program helps patients get access to their prescribed SohonosTM (palovarotene) with the information and support they need. SOHONOS is a prescription medicine used to reduce the amount of new heterotopic ossification in adults and children 8 years of age and older for females and 10 years and older for males with... SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. Do not take SOHONOS if you are pregnant, or allergic to medicines known as retinoids or any of the ingredients in SOHONOS.

We are collecting personal information to fulfill your request. Please see our Privacy Policy and our State Supplemental Privacy Policy for more information. Erin, patient living with fibrodysplasia ossificans progressiva (FOP), and her mother, Lori, United States After being prescribed SOHONOS®, talk to your health care team about enrolling into IPSEN CARES®. If you are eligible, you will receive a call from IPSEN CARES® confirming your enrolment into the program and offering additional information on services provided. You will have ongoing access to the services outlined above.

To request Medical Information or report a Product Quality Complaint for Ipsen Canada’s products, please contact Ipsen Canada at: If you think you or someone you know has experienced an adverse reaction to an Ipsen product, please contact Ipsen Canada at: SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and children (aged 8 years and above for females and 10... SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. More information to guide you in your SOHONOS journey. Keep track of your daily dose, and any dose changes.

Track changes in your health, dose, and potential side effects. Monitor the location, severity, and duration of your flare-ups. Your healthcare provider will complete the remainder of the form and fax the appropriate pages to IPSEN CARES. Once a completed Enrollment Form is received, an IPSEN CARES Patient Access Manager will perform a benefits verification and review the patient’s coverage and out-of-pocket responsibility with both the prescriber and the patient, typically... To learn more about IPSEN CARES and support offerings, please call (866) 435-5677, Monday – Friday, 8:00 AM – 8:00 PM ET or visit IPSENCARES.com. Your Enrollment Form request has been submitted to IPSEN CARES for review.

A Patient Access Manager will review your submission and contact both you and your Healthcare Provider within 1 business day. If you have any questions or would like to learn more about IPSEN CARES and its support offerings, please call (866) 435-5677, 8:00am to 8:00pm ET Monday through Friday. IPSEN CARES PATIENT ASSISTANCE PROGRAM APPLICATION (Required for patients seeking to participate in the Patient Assistance Program) The Patient Assistance Program (PAP) is designed to provide SOHONOS at no cost to eligible patients. Patients may be eligible to receive free drug if they are experiencing financial hardship and meet financial eligibility criteria, are uninsured or functionally uninsured, residents of the U.S., and received a valid prescription for... Eligibility does not guarantee approval for participation in the program.

Free SOHONOS provided by the PAP is intended only for the patient named in the application and must not be sold, transferred, or otherwise diverted. Patients must not seek reimbursement for the free drug provided by the PAP. The PAP provides SOHONOS product only, and does not cover the cost of previously purchased product or medical services. The PAP is not insurance. By submitting an application for the PAP, patient agrees to abide by these program terms. SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and children (aged 8 years and above for females and 10...

SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. Ask your doctor if SOHONOS is right for you. This illustration was co-created with people living with FOP. What is the most important information I should know about SOHONOS? SOHONOS can cause birth defects (deformed babies) if taken during pregnancy. Females who are pregnant or who plan to become pregnant must not take SOHONOS.

SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and children (aged 8 years and above for females and 10... SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. In the trial, people with FOP were treated with SOHONOS and their doctor and care team assessed how much new heterotopic ossification (HO) was forming in their bodies. This illustration was co-created with people living with FOP. People with FOP received 5 mg of SOHONOS daily. Their daily dose was increased if they experienced a flare-up (at least one symptom [eg, pain, swelling, redness] consistent with a previous flare-up) or a substantial high-risk traumatic event likely to lead to a...

Flare-up dosing was 20 mg once daily for 4 weeks followed by 10 mg once daily for 8 weeks.

People Also Search

SOHONOS Is FDA Approved To Reduce The Amount Of New

SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and children (aged 8 years and above for females and 10... SOHONOS is not recommended for females younger than 8 years of age or males younger than 10 years of age. Patient Education Liaisons (PELs) are healthcare educators who can provide educational informat...

I Am 18 Years Or Older, A US Resident, And

I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Privacy Policy. I understand that Ipsen will use reasonable measures to protect the information I share with the PEL and will not use or disclose it outside of Ipsen. The IPSEN CARES® Patient Support Program helps patients get access to their prescribed SohonosTM (palovarotene) wi...

We Are Collecting Personal Information To Fulfill Your Request. Please

We are collecting personal information to fulfill your request. Please see our Privacy Policy and our State Supplemental Privacy Policy for more information. Erin, patient living with fibrodysplasia ossificans progressiva (FOP), and her mother, Lori, United States After being prescribed SOHONOS®, talk to your health care team about enrolling into IPSEN CARES®. If you are eligible, you will receive...

To Request Medical Information Or Report A Product Quality Complaint

To request Medical Information or report a Product Quality Complaint for Ipsen Canada’s products, please contact Ipsen Canada at: If you think you or someone you know has experienced an adverse reaction to an Ipsen product, please contact Ipsen Canada at: SOHONOS is FDA approved to reduce the amount of new bone formation of heterotopic ossification or HO (growth outside the skeleton) in adults and ...

Track Changes In Your Health, Dose, And Potential Side Effects.

Track changes in your health, dose, and potential side effects. Monitor the location, severity, and duration of your flare-ups. Your healthcare provider will complete the remainder of the form and fax the appropriate pages to IPSEN CARES. Once a completed Enrollment Form is received, an IPSEN CARES Patient Access Manager will perform a benefits verification and review the patient’s coverage and ou...